GlassScriptPhysician profile
Andre D Duplantis
NPI 1558579268
$4,254.89
in general payments reported to CMS, 2019-2025
35 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $375 · 2021: $452 · 2023: $191 · 2024: $962 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,049.82 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $696.00 | 2019-2025 | Farxiga |
| Allergan, INC. | $266.77 | 2019-2020 | |
| Amgen INC. | $244.45 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $230.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.28 | 2025 | Caplyta |
| Pfizer INC. | $181.28 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.42 | 2019-2025 | Xifaxan, Cycloset, Trulance |
| Glaxosmithkline, LLC. | $119.28 | 2020-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $93.05 | 2025 | Auvelity |
| Ironwood Pharmaceuticals, INC | $91.94 | 2019 | |
| Astellas Pharma US INC | $87.39 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.26 | 2019-2021 | |
| Amarin Pharma, INC. | $78.10 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $72.00 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $63.35 | 2024-2025 | Ozempic, Rybelsus |
| Supernus Pharmaceuticals, INC. | $56.73 | 2025 | Qelbree |
| Sanofi-Aventis U.S. LLC | $53.56 | 2019-2021 | |
| Dexcom, INC. | $46.94 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $44.50 | 2019 | |
| Mylan Specialty L.P. | $40.80 | 2023-2024 | Yupelri |
| Exact Sciences Corporation | $34.18 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $30.53 | 2024-2025 | |
| Abiomed | $30.40 | 2023 | Impella |
| Novartis Pharmaceuticals Corporation | $29.60 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $27.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $24.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.48 | 2024 | Eliquis |
| Verona Pharma, INC. | $20.00 | 2025 | Ohtuvayre |
| Vanda Pharmaceuticals INC. | $19.05 | 2025 | Fanapt |
| Abbott Laboratories | $18.19 | 2024 | Freestyle Libre |
| Tolmar, INC. | $15.68 | 2024 | |
| Janssen Pharmaceuticals, INC | $15.00 | 2020 | |
| Endo Pharmaceuticals INC. | $14.29 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Duplantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.